SEC Info - Anika Therapeutics, Inc. - ‘10-K’ for 12/31/20

Anika Therapeutics, Inc. – ‘10-K’ for 12/31/20 – ‘R18’

On: Friday, 3/5/21, at 5:18pm ET · For: 12/31/20 · Accession #: 1171843-21-1573 · File #: 1-14027

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/21 Anika Therapeutics, Inc. 10-K 12/31/20 105:11M Globenewswire Inc./FA

Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.34M 6: EX-10.13D Material Contract HTML 94K 7: EX-10.13E Material Contract HTML 93K 8: EX-10.13G Material Contract HTML 85K 9: EX-10.13H Material Contract HTML 93K 2: EX-23.1 Consent of Expert or Counsel HTML 29K 3: EX-31.1 Certification -- §302 - SOA'02 HTML 35K 4: EX-31.2 Certification -- §302 - SOA'02 HTML 36K 5: EX-32.1 Certification -- §906 - SOA'02 HTML 30K 16: R1 Document And Entity Information HTML 89K 17: R2 Consolidated Balance Sheets HTML 112K 18: R3 Consolidated Balance Sheets (Parentheticals) HTML 47K 19: R4 Consolidated Statements of Operations and HTML 108K Comprehensive Income (Loss) 20: R5 Consolidated Statements of Stockholders' Equity HTML 85K 21: R6 Consolidated Statements of Cash Flows HTML 152K 22: R7 Note 1 - Nature of Business HTML 35K 23: R8 Note 2 - Summary of Significant Accounting HTML 118K Policies 24: R9 Note 3 - Business Combinations HTML 100K 25: R10 Note 4 - Fair Value Measurements HTML 90K 26: R11 Note 5 - Inventories HTML 44K 27: R12 Note 6 - Property and Equipment HTML 44K 28: R13 Note 7 - Acquired Intangible Assets, Net HTML 85K 29: R14 Note 8 - Goodwill HTML 47K 30: R15 Note 9 - Leases HTML 79K 31: R16 Note 10 - Accrued Expenses HTML 43K 32: R17 Note 11 - Revolving Credit Agreement HTML 35K 33: R18 Note 12 - Commitments and Contingencies HTML 34K 34: R19 Note 13 - Revenue by Product Group, by Significant HTML 87K Customer and by Geographic Location; Geographic Information 35: R20 Note 14 - Equity Incentive Plan HTML 108K 36: R21 Note 15 - Employee Benefit Plan HTML 33K 37: R22 Note 16 - Accelerated Share Repurchases HTML 36K 38: R23 Note 17 - Income Taxes HTML 120K 39: R24 Note 18 - Earnings Per Share ("Eps") HTML 43K 40: R25 Note 19 - Quarterly Financial Data (Unaudited) HTML 67K 41: R26 Significant Accounting Policies (Policies) HTML 171K 42: R27 Note 2 - Summary of Significant Accounting HTML 52K Policies (Tables) 43: R28 Note 3 - Business Combinations (Tables) HTML 81K 44: R29 Note 4 - Fair Value Measurements (Tables) HTML 85K 45: R30 Note 5 - Inventories (Tables) HTML 42K 46: R31 Note 6 - Property and Equipment (Tables) HTML 42K 47: R32 Note 7 - Acquired Intangible Assets, Net (Tables) HTML 79K 48: R33 Note 8 - Goodwill (Tables) HTML 39K 49: R34 Note 9 - Leases (Tables) HTML 76K 50: R35 Note 10 - Accrued Expenses (Tables) HTML 41K 51: R36 Note 13 - Revenue by Product Group, by Significant HTML 86K Customer and by Geographic Location; Geographic Information (Tables) 52: R37 Note 14 - Equity Incentive Plan (Tables) HTML 102K 53: R38 Note 17 - Income Taxes (Tables) HTML 115K 54: R39 Note 18 - Earnings Per Share ("Eps") (Tables) HTML 40K 55: R40 Note 19 - Quarterly Financial Data (Unaudited) HTML 65K (Tables) 56: R41 Note 2 - Summary of Significant Accounting HTML 72K Policies (Details Textual) 57: R42 Note 2 - Summary of Significant Accounting HTML 39K Policies - Allowance for Doubtful Accounts (Details) 58: R43 Note 2 - Summary of Significant Accounting HTML 39K Policies - Estimated Useful Lives of Property and Equipment (Details) 59: R44 Note 3 - Business Combinations (Details Textual) HTML 74K 60: R45 Note 3 - Business Combinations - Consideration HTML 41K Transferred (Details) 61: R46 Note 3 - Business Combinations - Fair Value of Net HTML 74K Assets Acquired (Details) 62: R47 Note 3 - Business Combinations - Intangible Assets HTML 43K Acquired (Details) 63: R48 Note 3 - Business Combinations - Pro Forma HTML 32K Information (Details) 64: R49 Note 4 - Fair Value Measurements (Details Textual) HTML 68K 65: R50 Note 4 - Fair Value Measurements - Fair Value of HTML 62K Financial Instruments (Details) 66: R51 Note 4 - Fair Value Measurements - Contingent HTML 38K Consideration (Details) 67: R52 Note 5 - Inventories (Details Textual) HTML 34K 68: R53 Note 5 - Inventories - Summary of Inventories HTML 41K (Details) 69: R54 Note 6 - Property and Equipment (Details Textual) HTML 30K 70: R55 Note 6 - Property and Equipment - Property and HTML 43K Equipment at Cost (Details) 71: R56 Note 7 - Acquired Intangible Assets, Net (Details HTML 50K Textual) 72: R57 Note 7 - Acquired Intangible Assets, Net - Summary HTML 63K of Intangible Assets (Details) 73: R58 Note 8 - Goodwill (Details Textual) HTML 32K 74: R59 Note 8 - Goodwill - Changes in the Carrying Value HTML 38K of Goodwill (Details) 75: R60 Note 9 - Leases (Details Textual) HTML 32K 76: R61 Note 9 - Leases - Lease Expense and Other HTML 58K Information (Details) 77: R62 Note 9 - Leases - Future Minimum Rental Payments HTML 95K for Operating Leases (Details) 78: R63 Note 10 - Accrued Expenses - Summary of Accrued HTML 45K Expenses (Details) 79: R64 Note 11 - Revolving Credit Agreement (Details HTML 63K Textual) 80: R65 Note 12 - Commitments and Contingencies (Details HTML 30K Textual) 81: R66 Note 13 - Revenue by Product Group, by Significant HTML 35K Customer and by Geographic Location; Geographic Information (Details Textual) 82: R67 Note 13 - Revenue by Product Group, by Significant HTML 50K Customer and by Geographic Location; Geographic Information - Product Revenue by Product Group (Details) 83: R68 Note 13 - Revenue by Product Group, by Significant HTML 47K Customer and by Geographic Location; Geographic Information - Total Revenue by Geographic Location (Details) 84: R69 Note 13 - Revenue by Product Group, by Significant HTML 34K Customer and by Geographic Location; Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) 85: R70 Note 14 - Equity Incentive Plan (Details Textual) HTML 131K 86: R71 Note 14 - Equity Incentive Plan - Granted and HTML 48K Exercised Stock-based Compensation Awards (Details) 87: R72 Note 14 - Equity Incentive Plan - Stock Options HTML 50K and SAR's Activity (Details) 88: R73 Note 14 - Equity Incentive Plan - Summary of HTML 41K Exercisable Options and SAR's (Details) 89: R74 Note 14 - Equity Incentive Plan - Restricted Stock HTML 50K Activity (Details) 90: R75 Note 14 - Equity Incentive Plan - Assumptions Used HTML 42K to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) 91: R76 Note 14 - Equity Incentive Plan - Total HTML 36K Stock-based Compensation Expense (Details) 92: R77 Note 15 - Employee Benefit Plan (Details Textual) HTML 33K 93: R78 Note 16 - Accelerated Share Repurchases (Details HTML 72K Textual) 94: R79 Note 17 - Income Taxes (Details Textual) HTML 59K 95: R80 Note 17 - Income Taxes - Components of Income HTML 63K Before Taxes and Provision for (Benefit from) Income Taxes (Details) 96: R81 Note 17 - Income Taxes - Significant Components of HTML 62K Company's Deferred Tax Assets and Liabilities (Details) 97: R82 Note 17 - Income Taxes - Reconciliation Between HTML 52K U.S. Federal Statutory Rate and Effective Rate (Details) 98: R83 Note 18 - Earnings Per Share ("Eps") (Details HTML 34K Textual) 99: R84 Note 18 - Earnings Per Share ("EPS") - Basic and HTML 38K Diluted Earnings Per Share (Details) 100: R85 Note 19 - Quarterly Financial Data (Unaudited) HTML 34K (Details Textual) 101: R86 Note 19 - Quarterly Financial Data (Unaudited) - HTML 67K Quarterly Financial Data (Unaudited) (Details) 103: XML IDEA XML File -- Filing Summary XML 199K 15: XML XBRL Instance -- anik20201231_10k_htm XML 2.55M 102: EXCEL IDEA Workbook of Financial Reports XLSX 118K 11: EX-101.CAL XBRL Calculations -- anik-20201231_cal XML 186K 12: EX-101.DEF XBRL Definitions -- anik-20201231_def XML 1.68M 13: EX-101.LAB XBRL Labels -- anik-20201231_lab XML 1.36M 14: EX-101.PRE XBRL Presentations -- anik-20201231_pre XML 1.72M 10: EX-101.SCH XBRL Schema -- anik-20201231 XSD 250K 104: JSON XBRL Instance as JSON Data -- MetaLinks 456± 766K 105: ZIP XBRL Zipped Folder -- 0001171843-21-001573-xbrl Zip 374K

Note 12 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

12. Commitments and Contingencies

Warranty and Guarantor Arrangements

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate or breach any U.S. or international patent or intellectual property rights, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company has no accrued warranties at December 31, 2020 or 2019, respectively, and has no history of claims paid.

Legal Proceedings

The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of potential legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.

This ‘10-K’ Filing

Date

Other Filings

Filed on:

3/5/21

For Period end:

12/31/20

10-K/A

List all Filings

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/24 Anika Therapeutics, Inc. 10-K 12/31/23 90:9.1M Globenewswire Inc./FA 3/16/23 Anika Therapeutics, Inc. 10-K 12/31/22 97:10M Globenewswire Inc./FA 3/11/22 Anika Therapeutics, Inc. 10-K 12/31/21 105:25M Globenewswire Inc./FA 5/07/21 Anika Therapeutics, Inc. 10-Q 3/31/21 67:5.1M Globenewswire Inc./FA 4/26/21 Anika Therapeutics, Inc. 10-K/A 12/31/20 100:10M Globenewswire Inc./FA

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/05/20 Anika Therapeutics, Inc. 8-K:5,7,9 8/05/20 3:95K Globenewswire Inc./FA 6/18/20 Anika Therapeutics, Inc. 8-K:5,9 6/16/20 2:194K Globenewswire Inc./FA 5/22/20 Anika Therapeutics, Inc. 10-Q 3/31/20 77:4.8M Globenewswire Inc./FA 4/29/20 Anika Therapeutics, Inc. 8-K:1,5,7,9 4/23/20 3:147K Globenewswire Inc./FA 3/06/20 Anika Therapeutics, Inc. 10-K 12/31/19 98:6.4M Globenewswire Inc./FA 3/02/20 Anika Therapeutics, Inc. 8-K:5,9 2/25/20 2:53K Globenewswire Inc./FA 1/07/20 Anika Therapeutics, Inc. 8-K:1,9 1/04/20 3:1.2M Globenewswire Inc./FA 7/26/19 Anika Therapeutics, Inc. 10-Q 6/30/19 68:3.4M Globenewswire Inc./FA 7/10/19 Anika Therapeutics, Inc. 8-K:5 7/05/19 3:131K Globenewswire Inc./FA 6/20/19 Anika Therapeutics, Inc. 8-K:5,9 6/18/19 2:185K Globenewswire Inc./FA 4/12/19 Anika Therapeutics, Inc. 8-K:5,9 4/09/19 5:230K Globenewswire Inc./FA 7/31/18 Anika Therapeutics, Inc. 10-Q 6/30/18 62:2.9M Globenewswire Inc./FA 6/06/18 Anika Therapeutics, Inc. 8-K:5,8,9 5/31/18 4:323K Globenewswire Inc./FA 3/08/18 Anika Therapeutics, Inc. 8-K:5,8,9 3/02/18 4:141K Globenewswire Inc./FA 10/27/17 Anika Therapeutics, Inc. 10-Q 9/30/17 66:4.1M Globenewswire Inc./FA 7/27/17 Anika Therapeutics, Inc. 8-K:5,7,9 7/27/17 3:116K Business Wire/FA 6/19/17 Anika Therapeutics, Inc. 8-K:5,9 6/13/17 6:320K Globenewswire Inc./FA 2/24/17 Anika Therapeutics, Inc. 10-K 12/31/16 86:5.9M Globenewswire Inc./FA 5/03/16 Anika Therapeutics, Inc. 10-Q 3/31/16 65:2.6M Globenewswire Inc./FA 10/14/15 Anika Therapeutics, Inc. 8-K:1,9 10/09/15 2:252K Business Wire/FA 5/05/14 Anika Therapeutics, Inc. 10-Q 3/31/14 61:3.5M Globenewswire Inc./FA 12/22/11 Anika Therapeutics, Inc. 8-K:1,9 12/21/11 3:832K Business Wire/FA 6/10/11 Anika Therapeutics, Inc. 8-K:5,9 6/07/11 2:108K Business Wire/FA 3/16/11 Anika Therapeutics, Inc. 10-K 12/31/10 10:2M Business Wire/FA 1/06/10 Anika Therapeutics, Inc. 8-K:1,2,3,912/30/09 7:1.4M Business Wire/FA 9/14/09 Anika Therapeutics, Inc. 8-K:5 9/10/09 3:108K Business Wire/FA 10/22/08 Anika Therapeutics, Inc. 8-K:5 10/17/08 3:249K Business Wire/FA 3/12/08 Anika Therapeutics, Inc. 10-K 12/31/07 8:784K Toppan Merrill-FA 2/06/08 Anika Therapeutics, Inc. 8-K:1,5,9 1/31/08 4:794K Toppan Merrill/FA 1/10/07 Anika Therapeutics, Inc. 8-K:1,2,9 1/04/07 2:489K Toppan Merrill/FA 10/05/04 Anika Therapeutics, Inc. 8-K:1,5,9 9/29/04 6:201K Toppan Merrill/FA 3/30/04 Anika Therapeutics, Inc. 10-K 12/31/03 8:741K Toppan Merrill-FA

Anika Therapeutics, Inc. – ‘10-K’ for 12/31/20 – ‘R18’

On: Friday, 3/5/21, at 5:18pm ET · For: 12/31/20 · Accession #: 1171843-21-1573 · File #: 1-14027

Previous ‘10-K’: ‘10-K’ on 3/6/20 for 12/31/19 · Next: ‘10-K/A’ on 4/26/21 for 12/31/20 · Latest: ‘10-K/A’ on 4/26/24 for 12/31/23 · 37 References:

Annual Report — Form 10-K
Filing Table of Contents

‘R18’ — Note 12 – Commitments and Contingencies

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

5 Subsequent Filings that Reference this Filing

32 Previous Filings that this Filing References

Anika Therapeutics, Inc. – ‘10-K’ for 12/31/20 – ‘R18’

On: Friday, 3/5/21, at 5:18pm ET · For: 12/31/20 · Accession #: 1171843-21-1573 · File #: 1-14027

Annual Report — Form 10-KFiling Table of Contents

‘R18’ — Note 12 – Commitments and Contingencies

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

5 Subsequent Filings that Reference this Filing

32 Previous Filings that this Filing References

Annual Report — Form 10-K
Filing Table of Contents